SHENZHEN, China, Dec. 7 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com is using this opportunity to update its followers on the development of several previously announced events, which remain unresolved and or pending. These are Slavica Biochem's move into the Revenue Mode, Slavica's research expansion and pending EU Stem Cell Bank merger, HTDS' Africa Opportunity, HTDS' Pink Sheets "skull and bones" rankings, and the expected Q4 results.
HTDS and Slavica Biochem plan to start capitalizing on Slavica's research and move from purely Research and Development Mode into a Revenue Mode. Slavica Biochem wants to take full advantage of its research achievements. Its management foresees the first revenues commencing in 2010.
HTDS management also continues due diligence with the EU stem cell company regarding the merger discussions. In the light of these discussions, Slavica is exploring an opportunity to either commence its own stem cell bank, or in a capacity as a consultant - advisor to other European companies venturing in the stem cell marketplace. Both options will afford the company with an opportunity to generate substantial revenues without any dilution.
HTDS management is also exploring the options of expanding Slavica's research activity. This newly discussed project focuses on the methodplogy for treatment of damaged articular cartilage, namely, this medical process, which consists of autologous implantation of in-vitro cultivated chondrocytes (the cartilage-forming cells). This new technique is one of the most important orthopaedic achievements of this century. See Pink Sheets Filing November 24 2009 http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=26604
The research team from Slavica Biochem continues discussions for technology sharing with an EU based bio company that already deploys this technology into practice.
HTDS also wants to bring the attention back to the 'Africa Opportunity' filling form October 16, 2009. http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=25196
In order to meet the growing demands of the sub-Saharan Africa, the International Finance Corporation (http://www.ifc.org/) estimated that the region's health care, relying strongly on private sector, requires an investment of $25 to $30 billion USD, coming mainly from the US government. HTDS still explores the ways and means as how to prepare and fulfill any potential orders, and estimates its capacities and capabilities in order to capitalize from this opportunity.
Lastly, HTDS is considering to filing a formal complaint with USA regulators regarding the "Skull and Bones" ranking on Pink Sheets, as this ranking restricts certain normal trading activities of the security.
With recently announced contracts and the current contracts pending, which HTDS sees coming to fruition soon, the company expects a strong Q4 finish.
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, www.minamargroup.com
SOURCE Hard to Treat Diseases
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved